Overview

Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Multicenter, doubleblinded, randomized placebo-controlled study of arimoclomol in patients with Gaucher Disease Type 1 or 3
Phase:
Phase 2
Details
Lead Sponsor:
Orphazyme